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Crystal structure of the receptor-binding domain of
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Background: The large plasma proteinase inhibitors of the α2-macroglobulin
superfamily inhibit proteinases by capturing them within a central cavity of the
inhibitor molecule. After reaction with the proteinase, the
α-macroglobulin–proteinase complex binds to the α-macroglobulin receptor,
present in the liver and other tissues, and becomes endocytosed and rapidly
removed from the circulation. The complex binds to the receptor via recognition
sites located on a separate domain of approximately 138 residues positioned at
the C terminus of the α-macroglobulin subunit.
Results: The crystal structure of the receptor-binding domain of bovine α2-
macroglobulin (bRBD) has been determined at a resolution of 1.9 Å. The
domain primarily comprises a nine-strand β structure with a jelly-roll topology,
but also contains two small α helices.
Conclusions:  The surface patch responsible for receptor recognition is
thought to involve residues located on one of the two α helices of the bRBD as
well as residues in two of the β strands. Located on this α helix are two lysine
residues that are important for receptor binding. The structure of bRBD is very
similar to the approximately 100-residue C-terminal domain of factor XIII, a
transglutaminase from the blood coagulation system.
Introduction
The α-macroglobulins (αMs) are very large proteinase
inhibitors found in the plasma of vertebrates and inverte-
brates. The αMs exist as monomers, or as dimeric and
tetrameric assemblies of approximately 180 kDa subunits
(for recent reviews see [1,2]). Unlike active site directed
inhibitors, αMs inhibit proteinases by capturing them
inside a central cavity. The complex formation is initiated
by proteinase-mediated cleavage of an exposed peptide
stretch called the ‘bait’ region [3,4]. The bait region con-
tains cleavage sites for a number of proteinases of all four
classes (serine-, thiol-, metallo- and carboxyl-proteinases)
[5]. Cleavage of the bait region induces a conformational
change that causes the αM to wrap around the proteinase,
thereby forming a large cavity. Proteinases, although still
reactive towards small substrates that can diffuse into the
cavity, become covalently attached to the αM by the
reaction of ε-amino groups of exposed lysine residues
with an internal thiol ester that becomes activated upon
cleavage of the bait region [6,7]. Upon inhibition of the
proteinase, αMs expose a C-terminal domain termed the
receptor-binding domain (RBD) [8,9]. The αM–protein-
ase complex then binds via this RBD to the α2M-receptor/
low-density lipoprotein receptor-related protein (α2MR/
LRP) [10–12], becoming endocytosed and rapidly removed
from the circulation [13–17].
The α2M receptor is a member of the low-density lipo-
protein (LDL) receptor family. These receptors contain
many cysteine-rich epidermal growth factor (EGF) like
repeats as well as other cysteine-rich ligand-binding
repeats found in complement component C9 [18]. The
receptors from this family are multiliganded binding pro-
teins of diverse physiological functions [19]. They are
located in clathrin-coated pits, bind ligands in a calcium-
dependent manner, and are recycled upon internalisation
[20]. The ligand-binding repeats contain, in addition to
six cysteine residues forming disulfide bridges, a con-
served sequence of Ser-Asp-Glu [10]. From NMR
structure determination of the individual repeats, it is
known that one side of the repeats contain grouped nega-
tive charges including the glutamate residue from the
above conserved sequence [21]. Human α2MR/LRP is a
protein of approximately 600 kDa (consisting of two
chains of 515 kDa and 85 kDa) and arises from the pro-
cessing of a large precursor protein [22]. Human
α2MR/LRP contains a number of ligand-binding sites,
some of which may be overlapping [23–28]. The binding
site of α2M–proteinase complexes has been mapped to a
65 kDa cyanogen bromide (CNBr) fragment comprising
residues 776–1399 and consisting of a cluster of eight
complement type repeats, one EGF-type repeat in the
N terminus and two EGF-type repeats in the C terminus
[24]. Binding of α2M–proteinase complexes is inhibited
by the N-terminal domain of receptor-associated protein
(RAP) [25,29] and by lipoprotein lipase (LPL) [30] indi-
cating that these ligands bind to the same or overlapping
sites on α2MR/LRP.
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The RBD of human α2M [31] and bovine α2M [32] can
be obtained by digestion of their methylamine-inacti-
vated forms with papain. The domain from both species
readily crystallises, but only the bovine domain has been
found suitable for X-ray crystallographic investigations
[33]. In the recent low-resolution X-ray structure of
human methylamine-treated α2M [34] the RBD can be
seen as four elongated globular structures protruding
from the near-spherical main body of α2M. 
Here we report the X-ray crystallographic structure of
bovine RBD (bRBD) determined at 1.9 Å resolution, and
we identify a structural motif which most likely consti-
tutes the surface patch interacting with α2MR/LRP. Fur-
thermore, we find that the topology of bRBD is very
similar to that of a domain of the transglutaminase coagu-
lation factor XIII, suggesting an evolutionary relationship
between αMs and transglutaminases.
Results and discussion
Quality of the model
The crystal structure of bRBD was determined by the
multiple isomorphous replacement (MIR) method in con-
junction with density modification techniques (see Tables
1–3 and Materials and methods). The crystals contain two
molecules per asymmetric unit. bRBD is produced by pro-
teolytic cleavage of bovine α2-M. As there are two cleavage
sites the preparation is not homogenous and the crystals
contain both a long and a short form. The present model
contains 130 residues (residues 3–132) of the 138 residues
in the short form of bRBD. The numbering refers to that
of the short (major) form of bRBD [33], corresponding to
residues 1313–1451 of human α2M [35,36] (i.e. residue 1 of
bRBD corresponds to residue 1313 of human α2M). The
missing N-terminal residues (1 and 2) are probably part of a
flexible loop serving to separate the RBD from the rest of
the α2M subunit. The six residues constituting the addi-
tion to the short form (residues –1 to –6) and the C-termi-
nal residues (133–138) cannot be traced either. A total of
304 water molecules, of which one is buried in the middle
of the sandwich coordinated by Tyr38, as well as one
calcium ion, and two N-acetyl-β-D-glucosamine residues at
position Asn68 of one of the two molecules in the asym-
metric unit have been added resulting in an R factor of
19.47%, and an R free of 23.94% at 1.9 Å resolution. Of the
two possible N-linked carbohydrate groups on each mol-
ecule [32], only that attached to Asn68 of one of the mol-
ecules could be traced because it is positioned between the
two molecules in such a way that it has a defined structure.
A few areas still exist where the electron density for
solvent-exposed sidechains is undefined. In addition, three
amino acids (Arg66, Ser67 and Asn68) from the other mol-
ecule in the asymmetric unit constituting a loop exposed
to a solvent channel with an N-linked oligosaccharide
attached to Asn68 are very poorly defined. The two mol-
ecules in the asymmetric unit are related in such a way that
only one calcium ion is bound. This calcium ion probably
has no physiological importance as it is coordinated by
sidechains from both molecules in the asymmetric unit as
well as by four water molecules. Weakly defined N-acetyl-
β-D-glucosamine residues and amino acids upstream and
downstream to the 130 traced residues were to some extent
modelled as water molecules.
Residue 94, previously identified as phenylalanine [32],
did not fit the electron density, which rather suggested
the presence of threonine. This is substantiated by the
presence of a water molecule, which makes a hydrogen
bond to the sidechain oxygen atom. For position 87, where
serine was previously identified, additional electron density
suggested that its sidechain might be located in two differ-
ent rotamers, and for position 128, where asparagine was
previously identified, the electron density suggested a
smaller sidechain such as serine.
A reinvestigation of the sequences of a set of peptides
(residues 1–49, 50–62, 63–66, 67–71, 72–104, 105–112 and
113–133) isolated after gentle digestion of bRBD with
trypsin, revealed that in the material used for crystallisa-
tion position 94 was in fact a threonine. In addition, a thre-
onine at position 87 and a serine at position 128 were
found. The preparations of bovine α2M used as starting
material in this and a previous study (JJ Enghild, personal
communication) were in both cases obtained from the
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Table 1
Data processing statistics.
Data set λ (Å) dmax (Å) Nobs* Nunique† Rmerge (%)‡ Completeness (%)
Native cryotemperature 1.07 1.90 453,466 35,876 7.2 (26.5)§ 91.0 (82.6)§
Native room temperature 1.54 2.50 33,286 15,698 5.6 85.6
TMLA 1.54 2.75 23,860 10,501 6.3 78.2
OPt 1.54 2.50 33,552 15,698 8.3 86.0
*Nobs = the number of observed reflections. †Nunique = the number of
unique reflections. ‡Rmerge = Σ|Ii – 〈Ii〉| / Σ〈Ii〉, where 〈Ii〉 is the mean
value of the ith intensity measurement. §Values in parentheses are for
the highest resolution shell (1.97–1.90 Å). TMLA = trimethyl lead
acetate; OPt = chloro (2,2′:6′2″-terpyridine) platinum (II) chloride.
plasma of single animals. Hence, the sequence differences
observed could reflect allelic variation.
The stereochemistry of the model has been checked with
the program PROCHECK [37]. It was found that 88.4% of
the residues are in the most favoured regions of the
Ramachandran plot and one outlier (Ser67) is present.
Overall structure of bRBD
bRBD is a globular slightly elongated domain of approx-
imate dimensions 50 Å × 25 Å × 25 Å. About 45% of the
residues are found in β structure and only 10% in α struc-
ture. The rest of the protein forms loop regions. The
domain is arranged in two antiparallel β sheets that stack
face-to-face to form a β sandwich with jelly-roll topology
(Figures 1 and 2a). The N-linked glycosylation sites at
positions 68 and 88 are located in two loops in close prox-
imity to each other. Even though the glycosylation is
heterogenous, resulting in not fully occupied oligosaccha-
rides [33], clear electron density for one of the chains can
be seen in the maps. The two sheets are made up of β
strands of different lengths (Figure 2a). β Strands, 5, 6, 3, 8
and 9, forming one of the sheets have an average length of
six residues whereas the strands forming the other sheet
are on average three residues longer, except strand 4. The
longest α helix lies on top of the sandwich, closing a gap
into the core of the protein (Figure 1). The interface
between the two β sheets is made up mostly of hydro-
phobic residues. The Cys17–Cys131 disulphide bridge
connects strand 1 to strand 9 and stabilises the structure
[31]. Although in most αMs this bridge is conserved, its
structural role in rat α1M and mouse α2M is provided by a
pair of phenylalanine residues [32,38].
Proposed receptor-recognition site
In general, the interaction between mammalian αMs and
α2MR/LRP is not species specific [14–16,32,39], and
examination of the sequences of RBD from different
species show that they are strongly related [27,40,41].
This suggests that the surface segment of RBD that inter-
acts with α2MR/LRP has a common topology. Indeed,
when comparing the primary structure of these domains
(bovine α2M [32], human α2M [35,36], human pregnancy
zone protein (PZP) [42], rat α2M [43], mouse α2M [38],
rat α1M [44], murinoglobulins 1 and 2 [45] and rat α1I3
[46]) one side of the molecule has a strikingly conserved
strip of residues from the tip to the bottom (Figure 3).
The conserved strip can be divided into two patches, one
located at the upper end of the molecule and the other on
the lower middle part of the molecule. The latter forms a
hydrophobic patch enclosed by charged residues. From
recent studies of mutants of RBD it was found that
mutating Lys58→Ala resulted in a greatly reduced affin-
ity for binding to α2MR/LRP [40,41]. In one study,
mutating Lys62→Glu also resulted in diminished recep-
tor binding [40]. As reported in [41] mutating Lys62→Arg
reduced affinity to the so-called α2M signalling receptor
but not to α2MR/LRP. Moreover, no α2MR/LRP binding
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Table 3
Crystallographic data.
Parameters Values
Refinement statistics
Total number of reflections (33–1.9 Å) 35,876
Working set
Number of reflections 34,844
R factor (%) 19.47
Test set
Number of reflections 1032
Free R factor (%) 23.94
Total number of protein atoms 2038
Total number of sugar atoms 28
Total number of waters and Ca2+ atoms 304/1
Geometry statistics
Rms bond length (Å) 0.005
Rms bond angles (°) 1.619
Rms ∆B (bonded atoms), all atoms (Å2) 7.52
Rms ∆B (bonded atoms), mainchain (Å2) 5.70
Rms ∆B (bonded atoms), sidechain (Å2) 9.67
Average B factor, all atoms (Å2) 31.98
Average B factor, mainchain (Å2) 27.38
Average B factor, sidechain (Å2) 32.52
Average B factor, oligosaccharides (Å2) 57.71
Average B factor, waters and Ca2+ atoms (Å2) 45.72
Ramachandran plot
Residues in most favoured regions (%) 88.4
Residues in additional allowed regions (%) 11.2
Residues in generously allowed regions (%) 0.0
Residues in disallowed regions (%) 0.4
Table 2
Heavy-atom statistics.
Data set Soaking time Concentration Rdiff* Number of Rcullis† Phasing power‡
(h) (mM) sites (centric/acentric) (centric/acentric)
TMLA 96 20 0.20 3 0.69/0.68 1.30/1.77
OPt 24 5 0.18 2 0.83/0.88 0.68/0.88
*Rdiff = Σ||FPH| – |FP||/Σ|FP|, where FP and FPH are the native and
derivative structure factors, respectively. †Rcullis = Σ||FPH + FP| – |FH||/
Σ|FPH + FP|, where FP, FPH, and FH are the observed protein, derivative,
and calculated heavy-atom structure factors, with the sum over all
reflections. ‡Phasing power = |FH|/E. TMLA and OPt are as defined in
Table 1.
data were reported in [41] after mutating Lys62→Ile. In
view of the results reported in [40] it is suggested that
both Lys58 and Lys62 are important for receptor binding.
These two residues are located on the α helix between β
strands 4 and 5. Because of the topology of the α helix,
the two lysine residues are sticking out in an angle
approximately 45° from the molecular surface. In the
crystal structure there are no indications of electrostatic
interactions of the amino groups of these residues to
groups other than water molecules. 
Because of the very strong binding to the receptor [47] it
seems unlikely that the interaction is made up solely of
electrostatic interaction of the ε-amino groups with acidic
residues on the receptor. It therefore seems plausible
that receptor recognition is based on the hydrophobic
patch in conjunction with the charged residues. In this
way, receptor binding is mediated by both hydro-
phobic interaction and electrostatic binding. Most of the
residues supposed to be involved in receptor binding
(Figure 4) are located on a continuous stretch of amino
acids defining β strand 4, α helix B, and β strand 5,
forming what might be a structural motif for receptor
binding. This motif, continuous in sequence, is a three-
dimensional entity anchored on one side of the β-sand-
wich structure. The anchoring of the motif is probably
necessary to maintain the conformation required for
receptor binding. This is compatible with the previously
observed lack of receptor binding of isolated peptides
covering that region [31].
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Figure 1
The overall fold of bRBD. (a) Stereoview Cα
trace of bRBD; every tenth residue is
numbered. (b,c) The fold of bRBD from two
different views. β Strands and α helices are
depicted as purple and blue arrows and red
ribbons, respectively. Turns and loops are
shown as cords. (The figures were prepared
with the programs MOLSCRIPT [66] and
RASTER 3D [67].)
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Structure
The area of the proposed receptor recognition patch is
20 Å × 15 Å. Ovomacroglobulin from hen egg white does
not bind to human α2MR/LRP [39], and in a comparison of
the amino acid sequence of this protein to other αMs it was
pointed out [40] that Lys62 is not conserved in ovo-
macroglobulin [48]. Of the residues forming the hydro-
phobic patch, Ile55, Pro59, Val61 and Val74 are also not
conserved in ovomacroglobulin. This could explain the lack
of receptor-recognition ability and further substantiates the
proposed motif.
When comparing the structure of bRBD to that of the
N-terminal domain of RAP (RAPD1T) [49] no obvious
similarity is noted, as RAPD1T is a three-helix bundle.
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Figure 2
Comparison of the folds of bRBD and the C-terminal domain of factor
XIII. (a) Topological representation of bRBD. The two β sheets forming
the jelly roll are shown in purple and blue; α helices are in red. The
disulphide bridge connecting the sides of the sandwich is formed
between Cys17 and Cys131. N-linked glycosylation sites are located
at Asn68 and Asn88 and are marked with stars. (b) The C-terminal
domain of factor XIII. This structure portrays a jelly roll with a greek key
motif. The two β sheets are coloured purple and blue, and the
numbering of the strands is taken from the numbering of bRBD to
facilitate comparison. In the factor XIII domain there is no disulphide
bridge connecting the two sheets.
Figure 3
The two sides of the bRBD molecule.
Conserved residues of receptor-binding
domains of α-macroglobulins known to bind
α2MR/LRP are coloured according to atom
type, whereas non-conserved amino acids are
shown in grey. One side of the molecule
shows a strip of conserved residues proposed
to be involved in receptor recognition. (The
figures were prepared with the programs
MOLSCRIPT [66] and RASTER 3D [67].) 
1 2 7
4
5 6 3 8 9
13 25 99 54
6 34 91
56
74
71
78
83
49
44
109
115
127
122
21
24
58
65
NH2
Cys17 Cys131
COOH
1 2 7 6 3 8 9
NH2
COOH
B
A
Structure
(a) (b)
The residues of RAPD1T required for receptor binding
(1–24 and 100–107) [25] are not positioned in any way
comparable to the residues of the receptor-recognition
patch of bRBD. This indicates that the binding sites of
RAPD1T and bRBD are not identical but might be over-
lapping as earlier proposed [29].
The function of the other patch of conserved residues
cannot be deduced, but it might be involved in the posi-
tioning of RBD relative to the rest of α2M or in the spe-
cific movement that is required to expose the receptor-
binding patch of RBD upon transformation [34].
Structural comparisons to other proteins
A structure-based search for proteins with topology homol-
ogous to bRBD was performed with the program DALI
[50]. A few proteins were found to have the same approxi-
mate structure as that of bRBD. Of these, the RBD of
diphtheria toxin (root mean square deviation [rmsd] 3.1 Å)
[51] and part of the P domain of the capsid protein from
tomato bushy stunt virus (rmsd 3.1 Å) [52] have high struc-
tural similarity. Intriguingly, the C-terminal domain of the
A subunit of factor XIII (residues 627–727) [53] was found
to have a particularly high similarity score. The rmsd
between the 80 Cα positions superimposed is only 1.69 Å,
indicating that the three-dimensional structures are almost
the same for these domains. However, one major differ-
ence occurs at the region we propose here as the receptor-
recognition patch. The motif defining this patch is not
present in factor XIII (Figures 2 and 5) as the polypeptide
chain connects strands 3 and 6 in factor XIII. This lends
further credence to the hypothesis that the receptor-recog-
nition segment is made up of this particular motif. The
sequence similarity between the aligned Cα positions is
very sparse except for the expected hydrophobic residues
forming the core of the jelly roll β sandwich (Figure 6). 
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Figure 5
Stereoview showing a superposition of bRBD
and the C-terminal domain of factor XIII.
bRBD is shown in blue and factor XIII is in
grey. The β-α-β motif is located at the top of
the β sandwiches in this view, and is missing
in factor XIII. (The figure was prepared with
the program MOLSCRIPT [66].) 
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Figure 4
The patch of residues proposed to be involved in receptor recognition.
The residues (Ile55, Pro56, Leu57, Lys58, Pro59, Val61, Lys62, Val74,
Leu98 and Asp100) are shown in CPK representation with atoms in
standard colours. In order to emphasise the hydrophobicity of the
patch, the mainchain nitrogens and oxygens have been omitted from
the figure. All residues except Leu98 and Asp100 are located on the
β-α-β structural motif spanning residues 54 to 77. (The figure was
prepared with the programs MOLSCRIPT [66] and RASTER 3D [67].) 
Factor XIII is part of the blood coagulation system, where it
functions as a transglutaminase that catalyses the formation
of amide cross-links between glutamine and lysine residues
to provide structural stability to the blood clot [54].
Whether the topological equivalence between bRBD and
the C-terminal domain of factor XIII reflects an evolution-
ary relationship between αMs and transglutaminases, espe-
cially factor XIII, is not known. Intriguingly, both groups of
proteins utilise thiol esters in their reaction mechanism.
Before the formation of ε-lysyl-γ-glutamyl cross-links by
factor XIII, a thiol ester intermediate is formed with a glu-
tamyl moiety of one of the target proteins, thereby activat-
ing it for nucleophillic attack from an ε-lysyl amino group
[54]. αMs, on the other hand, contain a preformed ‘pseudo-
enzymatic’ reactive thiol ester site, which upon proteinase
complex formation is readily cleaved by ε-lysyl groups of
the proteinase being complexed or by other nucleophiles
present [6,7]. The distance from the centre of the domain
that corresponds to bRBD in factor XIII to the active site
where this thiol ester intermediate is formed is approxi-
mately 19 Å [53]. From the structure of transformed human
α2M determined at 10 Å resolution, the distance from the
thiol ester to the centre of the RBD, supposedly in the
same subunit, was found to be 78 Å [34]. If the two proteins
have evolved from a common ancestor it might be expected
that these distances would be similar. However, in the acti-
vation of factor XIII a conformational change is involved to
make the active site accessible. This conformational change
might indeed involve the C-terminal region of factor XIII
[53], so that the distance between the domain correspond-
ing to bRBD and the active site where the thiol ester inter-
mediate is formed is enlarged. However, neither the
structure of native α2M nor that of activated factor XIII are
available to provide conclusive evidence.
In conclusion, we have determined the X-ray crystallo-
graphic structure of bRBD at 1.9 Å resolution, and we
have tentatively located the surface patch interacting with
α2MR/LRP. Furthermore, we have found that bRBD is
topologically strongly related to the C-terminal domain of
coagulation factor XIII, suggesting an evolutionary rela-
tionship between αMs and transglutaminases. The bRBD
structure provides the first detailed structural information
on an αM domain, and will constitute the structural plat-
form for future investigations of the interactions of α2MR/
LRP not only with αMs but also with a multitude of seem-
ingly unrelated ligands. These results will also aid   inves-
tigations of the determinants of receptor recognition, and
of the mechanism of recognition-site exposure during
αM–proteinase complex formation.
Biological implications
The α-macroglobulins (αMs) are very large proteinase
inhibitors found in plasma. They inhibit proteinases by
trapping them inside a central cavity and thereby render-
ing the proteinase unable to interact with the substrate. In
order to trap the proteinase, the αM contains an exposed
stretch of amino acids called the ‘bait’ region. This bait
region contains cleavage sites for a number of proteinases
and upon cleavage the αM undergoes a conformational
change that traps the proteinase within a central cavity
and activates an internal thiol ester. A covalent bond is
formed by reaction of the thiol ester with lysine residues
on the exterior of the proteinase, thereby securing the
proteinase inside the cavity. Part of the conformational
change involves exposing the C-terminal region of the αM
subunit. This region is termed the receptor-binding domain
because it binds to the α2-macroglobulin receptor/low-
density lipoprotein receptor-related protein (α2MR/LRP),
following which the proteinase–inhibitor complex is endo-
cytosed and degraded.
The structure of the receptor-binding domain of bovine α2-
macroglobulin (bRBD) has been determined by X-ray
crystallography. The domain is primarily a β sandwich
comprising nine β strands with two small α helices. Lysine
residues important for binding to α2MR/LRP have earlier
been identified by mutagenesis studies, and these residues
can now be placed on the α helix closing the gap between
the two β sheets. These positively charged residues are
surrounded by hydrophobic residues which are highly
Research Article  a2-Macroglobulin receptor-binding domain Jenner et al. 601
Figure 6
Structural sequence alignment based on an overall superposition of
bRBD and the C-terminal domain of factor XIII. Non-superposable
residues are shown in small red letters. Strictly conserved residues are
shaded in black and semi-conserved residues are shaded in blue. Red
and blue bars above the sequences denote α helices and β strands,
respectively, in bRBD. Superposition was performed by least-squares
fitting using the program O [59]. 
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conserved in different species of αMs that all bind to the
human α2-macroglobulin receptor. We hypothesise that
the surface patch comprising these lysines as well as the
hydrophobic residues constitutes the receptor-recognition
area. Most of these residues are located on a continuous
stretch of amino acids forming a β-α-β motif and it there-
fore seems likely that this might be a structural motif for
binding to α2MR/LRP.
The fold of bRBD is very similar to that of the C-terminal
domain of factor XIII, a transglutaminase from the blood
coagulation system. The principal difference between the
two proteins is that the β-α-β motif is missing in factor
XIII. Transglutaminases utilise a thiol ester intermediate
in their reaction mechanism, and it has previously been
suggested that there might be a similarity between these
two groups of proteins. This is demonstrated here for the
first time by a structural comparison.
Materials and methods
Protein preparation and crystallisation
The preparation and crystallisation of bRBD have been described
previously [33]. Changing the buffers from Tris to Hepes throughout
the purification made the protein fragment more stable upon freezing,
so that instead of preparing a new batch of protein before each crys-
tallographic experiment, well diffracting crystals could still be grown
after thawing protein that had been kept frozen at –80°C for at least
one year. By changing the crystallisation conditions from 28% (w/v)
PEG 6000, pH 5.5–7.4 (100 mM Mes or Hepes titrated with Tris),
and 20 mM CaCl2 to 35% (w/v) PEG monomethyl ether 2000,
pH 6.4–7.4 (100 mM Hepes titrated with NaOH), and 20 mM CaCl2
the crystals become substantially larger (0.7 × 0.5 × 0.5 mm3) than
the ones previously obtained. 
Preparation and sequence analysis of tryptic peptides of bRBD
Approximately 50 nmol reduced and S-carboxymethylated bRBD dis-
solved in 100 mM Hepes pH 7.4 was digested for 3 h at room tempera-
ture with 1:200 mol/mol bovine trypsin affinity-purified on a benzamidine
–Sepharose column. The digest was separated by reverse-phase HPLC
on a 4 × 250 mm column packed with 5 µm Nucleosil C18 material using
gradient elution from 95% (v/v) 0.1% trifluoroacetic acid and 5% (v/v)
acetonitrile to 30% (v/v) 0.1% trifluoroacetic acid and 70% (v/v) aceto-
nitrile. All major peptide pools were subjected to sequence analysis using
an ABI 477A instrument connected on-line to an ABI 120A chromato-
graph operated as described previously [55].
Data collection and reduction
Data were collected at both room temperature and cryogenic temper-
atures using crystals with typical dimensions 0.5 × 0.5 × 0.5 mm3
(Table 1). The native room temperature data set and the two derivative
data sets were collected on a FAST area detector mounted on an Enraf
Nonius rotating anode X-ray generator. The source was operated at
40 kV and 70 mA using a focal spot size of 0.3 × 3 mm2. Monochro-
matic copper Kα radiation was obtained using a graphite crystal mono-
chromator. The data were processed using the MADNES program
package [56]. The high-resolution data set was collected on two crys-
tals at 100K. The crystals were frozen in a cryoprotective solution con-
sisting of 10% (v/v) glycerol added to the mother liquor. The transfer
was carried out in two steps with solutions of 1 and 10% glycerol. This
data set was collected at the beamline X-ray Diffraction, Elletra, Trieste,
Italy on a MAR Research imaging plate area detector. The wavelength
was 1.07 Å and the data were processed using the programs DENZO
and SCALEPACK [57].
The spacegroup of the crystals is P3121 with two molecules in the asym-
metric unit, giving rise to a solvent content of approximately 63%. The
cell parameters for the non-frozen native data set are a = b = 108.99 Å,
c = 72.30 Å and a = b = 105.70 Å, c = 72.23 Å for the frozen crystals.
Before heavy atom derivatisation the crystals were transferred to well
solution that served as stabilising buffer. Heavy atoms were either added
as a solid or solubilised in the stabilising buffer. Crystals soaked in chloro
(2,2′:6′,2′′-terpyridine) platinum(II) chloride (OPt) turned orange indicat-
ing that derivatisation had taken place, whereas soaking in trimethyl-lead
acetate (TMLA) did not cause a colour change.
Phase determination
Because of the differences in cell parameters between frozen and non-
frozen crystals it was necessary to base the structure determination and
model building on the non-frozen data. In an origin-removed sharpened
difference Patterson map of the TMLA derivative the self-vectors of the
main Pb site came up with a signal-to-noise ratio of 12 in a correspond-
ingly easy to interpret Patterson map. The difference Patterson was inter-
preted using programs from the CCP4 package [58]. After phasing with
the TMLA derivative, the Pt sites of the OPt derivative were found using
difference Fourier techniques. Phasing was performed using the program
MLPHARE. Table 2 shows the results from the phasing procedure. The
final average figure of merit, using both derivatives for phasing, was 0.48
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Figure 7
Experimental and final electron-density maps.
(a) The solvent-flattened and averaged
experimental map calculated at 2.9 Å. The
electron density has been contoured at one
(green) and two (white) times the rms value of
the density for the unit cell. As the model was
refined using the frozen crystal data with cell
parameters differing from the non-frozen data,
the final model has been placed in the
experimental density according to the
transformation found in the rigid-body
refinement. (b) 2Fobs– Fcalc map calculated at
1.9 Å from the final refined model. The map
has been contoured at 1.5σ (green) and 2.5σ
(white).
for 10 to 3.2 Å data. The phases were improved further by 50 cycles of
solvent flattening and phase extension to 2.9 Å using the program
SOLOMON. In the resulting MIR map the secondary structure elements
were recognisable and the two molecules of the asymmetric unit could
be identified. Twofold density averaging was performed on the solvent-
flattened map using the program package RAVE [59]. The map thus pro-
duced (Figure 7) was of very good quality and readily allowed tracing of
the polypeptide chain. 
Model building and refinement
The model of bRBD was build into the 2.9 Å averaged and solvent-flat-
tened map using the program O [60]. The structure was then refined in
an iterative procedure using alternately simulated annealing and posi-
tional refinement with non-crystallographic symmetry restraints in X-
PLOR [61] and model building into (2Fobs–Fcalc, αcomb) electron-density
maps. The combined phases were calculated by SIGMAA (CCP4
package) from the model and the solvent-flattened and averaged MIR
map. Using this procedure, 129 residues of 138 could be built.
In order to use the data set collected on the frozen crystals, rigid-body
refinement in X-PLOR was performed. All coordinates were shifted
approximately 1 Å. Again, simulated annealing and positional refinement
in X-PLOR were used. Maps were now prepared with calculated phases
as no experimental phases were available for this purpose. B factors
were refined as grouped B factors at first and later as individual B factors
as this decreased the free R factor [62] considerably. When the R factor
had dropped to 0.27 for 1.9 Å data, water molecules were added where
density showed up at 3σ in (Fobs – Fcalc) maps. The non-crystallographic
symmetry restraints were loosened for some loops and crystal contact
areas where differences between the two molecules were apparent.
After adding 137 water molecules and realising that one of the water
molecules actually was a calcium ion, the R factor dropped to 0.24 and
the free R factor to 0.29. The program SHELXL-97 [63] was now used
for least-squares refinement with all the data. The oligosaccharide chain
was built for one glycosylation site of one of the molecules, and an extra
residue was added (residue 3). Non-crystallographic symmetry restraints
were set loose and more water molecules to a total of 304 were added.
Bulk solvent correction [64] was used as well as anisotropic scaling of
the data [65]. The final Rfree is 23.94% and Rcryst 19.47% for all data
from 33 to 1.9 Å. Further crystallographic statistics are given in Table 3. 
Accession numbers
The atomic coordinates have been deposited with the Protein Data
Bank (accession code 1ayo).
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